Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 pathway

被引:86
作者
Luo, Haitao [1 ]
Rankin, Gary O. [2 ]
Juliano, Noelle [1 ]
Jiang, Bing-Hua [3 ]
Chen, Yi Charlie [1 ]
机构
[1] Alderson Broaddus Coll, Div Nat Sci, Philippi, WV 26416 USA
[2] Marshall Univ, Joan C Edwards Sch Med, Dept Pharmacol Physiol & Toxicol, Huntington, WV USA
[3] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA
基金
美国国家科学基金会;
关键词
Kaempferol; VEGF; Angiogenesis; ERK; ENDOTHELIAL GROWTH-FACTOR; CANCER; PERFORMANCE; QUERCETIN; FLAVONOLS; LUNG;
D O I
10.1016/j.foodchem.2011.07.045
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Kaempferol has been reported to reduce the risk of ovarian cancer, but the mechanism is not completely understood. In this study, we tend to expand our understanding on how kaempferol regulates VEGF expression and angiogenesis in ovarian cancer cells. We timed VEGF secretion, and studied in vitro angiogenesis by kaempferol treatment. Gene expression was examined by qRT-PCR, ELISA, western blotting, or luciferase assay, and pathways were examined by manipulating genetic components with plasmid or siRNA transfection. It was found that kaempferol time-dependently inhibited VEGF secretion, and suppressed in vitro angiogenesis. Kaempferol down-regulated ERK phosphorelation as well as NF kappa B and cMyc expression, but promoted p21 expression. Examination of relationship between these genes suggested a novel ERK-NF kappa B-cMyc-p21-VEGF pathway, which accounts for kaempferol's angioprevention effects in ovarian cancer cells. This data supplements our comprehension of the mechanisms behind kaempferol's biological influence in ovarian cancer cells, and better characterised kaempferol toward chemoprevention. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:321 / 328
页数:8
相关论文
共 22 条
[1]   Nuclear factor-κ-B:: The enemy within [J].
Aggarwal, BB .
CANCER CELL, 2004, 6 (03) :203-208
[2]  
[Anonymous], NCI CANC B 0308
[3]   CA 125: The past and the future [J].
Bast, RC ;
Xu, FJ ;
Yu, YH ;
Barnhill, S ;
Zhang, Z ;
Mills, GB .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (04) :179-187
[4]   Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention [J].
Bertl, E ;
Bartsch, H ;
Gerhäuser, C .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (03) :575-585
[5]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[6]   Comparative pharmacokinetics and bioavailability studies of quercetin, kaempferol and isorhamnetin after oral administration of Ginkgo biloba extracts, Ginkgo biloba extract phospholipid complexes and Ginkgo biloba extract solid dispersions in rats [J].
Chen, Zhi-peng ;
Sun, Jun ;
Chen, Hong-xuan ;
Xiao, Yan-yu ;
Liu, Dan ;
Chen, Jun ;
Cai, Hao ;
Cai, Bao-chang .
FITOTERAPIA, 2010, 81 (08) :1045-1052
[7]   Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens [J].
Cramer, Daniel W. ;
Bast, Robert C., Jr. ;
Berg, Christine D. ;
Diamandis, Eleftherios P. ;
Godwin, Andrew K. ;
Hartge, Patricia ;
Lokshin, Anna E. ;
Lu, Karen H. ;
McIntosh, Martin W. ;
Mor, Gil ;
Patriotis, Christos ;
Pinsky, Paul F. ;
Thornquist, Mark D. ;
Scholler, Nathalie ;
Skates, Steven J. ;
Sluss, Patrick M. ;
Srivastava, Sudhir ;
Ward, David C. ;
Zhang, Zhen ;
Zhu, Claire S. ;
Urban, Nicole .
CANCER PREVENTION RESEARCH, 2011, 4 (03) :365-374
[8]   Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways [J].
Fang, J ;
Xia, C ;
Cao, ZX ;
Zheng, JZ ;
Reed, E ;
Jiang, BH .
FASEB JOURNAL, 2005, 19 (03) :342-353
[9]  
Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
[10]   GENISTEIN, A DIETARY-DERIVED INHIBITOR OF INVITRO ANGIOGENESIS [J].
FOTSIS, T ;
PEPPER, M ;
ADLERCREUTZ, H ;
FLEISCHMANN, G ;
HASE, T ;
MONTESANO, R ;
SCHWEIGERER, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (07) :2690-2694